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Abstract
Context: Comparative reviews of whole-body magnetic resonance imaging (WB-MRI)
and positron emission tomography/computed tomography (CT; with different radio-
tracers) have shown thatmetastasis detection in advanced cancers ismore accurate than
with currently used CT and bone scans. However, the ability of WB-MRI and positron
emission tomography/CT to assess therapeutic benefits has not been comprehensively
evaluated. There is also considerable variability in the availability and quality of
WB-MRI, which is an impediment to clinical development. Expert recommendations
for standardising WB-MRI scans are needed, in order to assess its performance in
advanced prostate cancer (APC) clinical trials.
Objective: To design recommendations that promote standardisation and diminish
variations in the acquisition, interpretation, and reporting of WB-MRI scans for use
in APC.
Evidence acquisition: An international expert panel of oncologic imagers and oncolo-
gists with clinical and research interests in APC management assessed biomarker
requirements for clinical care and clinical trials. Key requirements for a workable
WB-MRI protocol, achievable quality standards, and interpretation criteria were identi-
ﬁed and synthesised in a white paper.
Evidence synthesis: The METastasis Reporting and Data System for Prostate Cancer
guidelines were formulated for use in all oncologic manifestations of APC.
Conclusions: Uniformity in imaging data acquisition, quality, and interpretation of
WB-MRI are essential for assessing the test performance of WB-MRI. The METastasisPlease visit www.eu-acme.org/
europeanurology to read and
answer questions on-line.
The EU-ACME credits will then
be attributed automatically.
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Reporting and Data System for Prostate Cancer standard requires validation in clinical trials
of treatment approaches in APC.
Patient summary: METastasis Reporting and Data System for Prostate Cancer represents
the consensus recommendations on the performance, quality standards, and reporting
of whole-body magnetic resonance imaging, for use in all oncologic manifestations of
advanced prostate cancer. These new criteria require validation in clinical trials of estab-
lished and new treatment approaches in advanced prostate cancer.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Several therapeutic approaches have received recent
regulatory approval for use in men with advanced prostate
cancer (APC) [1]. In addition to continued androgen
deprivation and docetaxel treatments, there are now
additional agents with varying mechanisms of action
showing survival benefit in this patient population. These
include agents that target the androgen axis (eg, enzalu-
tamide and abiraterone), stimulate the immune system
(eg, sipuleucel-T), have a chemotherapeutic effect (eg,
docetaxel and cabazitaxel), and the alpha-particle emitter
that directly targets bone metastases (eg, radium-223)
[2,3]. Response to these agents is not universal with
significant proportions of patients having primary resis-
tance, and virtually all patients developing secondary
resistance at variable times after treatment commence-
ment. The optimal use of these therapies remains debatable
[4,5] with the presence, volume, and location of metastases
being important determinants.
The imaging depicted metastatic state is key to patient
management for biomarker (BM) development and for
therapeutic clinical trials [6–8]. Imaging BMs provide
information on disease volume and distribution, likely
prognosis, changes in biologic behaviour, therapy-induced
changes (both benefits and nonbenefits), durations of
response, emergence of treatment resistance, and the host’sTable 1 – Imaging impacts on advanced prostate cancer management
Impact statements
Imaging deﬁnes clinical groups for drug and biomarker development and clinica
therapy recommendations
The anatomic location of metastases in CRPC is highly prognostic, adding to prog
models predicting overall survival to docetaxel treatment
The presence of visceral disease and/or large volume nodal metastases precludes
radium-223
Therapeutic beneﬁts using androgen axis directed treatments in asymptomatic/m
symptomatic, chemotherapy naı¨ve, metastatic prostate cancer patients are oft
those with better performance status and lower disease volume on bone and C
High volume disease patients on imaging have worse survival than lower volum
patients (no matter which imaging test is used to make the determination)
The presence of high volume and visceral disease on imaging is an indication fo
combination therapy, including chemotherapy in ﬁt patients
Shorter imaging durations of response to abiraterone and docetaxel treatments u
scans and the more objective size based RECIST criteria for soft tissue disease,
with worse overall survival
CRPC = castration resistant prostate cancer; CT = computed tomography; RECISTreaction to the therapies administered. Numerous investi-
gators have subcategorised the metastatic state in APC, by
tissue involvement (bone/lymph nodes/visceral), by skeletal
location (axial/peripheral), by number of lesions (oligometa-
static or polymetastatic), and by the overall burden/volume
of disease, because these have been shown to have
prognostic and therapeutic value as summarised in Table 1.
Recent reviews have identified the potential of whole-
body magnetic resonance imaging (WB-MRI) and positron-
emission tomography/computed tomography (PET/CT), to
address the unmet need for robust imaging that allows
tumour detection and therapy evaluations in APC [9,10]. In
particular, it has been noted that WB-MRI can detect bone
metastases with higher sensitivity than bone scans and
with at least comparable performance to choline PET/CT
[11]. Importantly,WB-MRI provides a clearer categorisation
of bonemetastases response, unlike bone scans and sodium
fluoride PET/CT scans that only identify disease progression.
More accurate assessments of therapy response (including
the detection of primary and secondary resistance and
heterogeneity of response) could aid in the rationale
development of targeted therapies [8]. Two recent reviews
have indicated that WB-MRI is suitable for wider deploy-
ment in disease detection settings, given its established test
performance, potential for wide availability, and multi-
organ evaluation capabilities [9,10]. The European Organi-
sation for Research and Treatment of Cancer position paperReferences
l states for Scher et al. [8]; Cookson et al. [25]
nostic Halabi et al. [6,26]
use of Parker et al. [27]
ildly
en greater for
T scans
de Bono et al. [28]; Beer et al. [29]; James et al. [30];
Ryan et al. [31]; Evans et al. [7]
e disease Dennis et al. [32]; Sweeney et al. [33]; Ceci et al. [34];
Tait et al. [35]; Sabbatini et al. [36];
Perez-Lopez et al. [37]; Evans et al. [7]
r intensiﬁed Sweeney et al. [33]; Aparicio et al. [38]; James et al. [30]
sing bone
are associated
Morris et al. [39]; Sonpavde et al. [40]
= Response Evaluation Criteria in Solid Tumours.
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for assessing therapy effectiveness in APC [10]. The need for
standardisation of WB-MRI technology has also been
expressed by multiple groups [5,9,10,12,13].
2. Evidence acquisition
2.1. WB-MRI for clinical practise and clinical trials in APC
An expert panel of radiologists, nuclear medicine physi-
cians, and medical physicists, with the largest experience
of imaging in APC, conducted a review of the performance,
merits, and limitations of currently available imaging
methods [9]. As part of the imaging review, guidelines
were formulated on the performance standards for
WB-MRI in the assessment of multi-organ involvement
by APC.
The METastasis Reporting and Data System for Prostate
Cancer (MET-RADS-P) imaging recommendations are
designed to promote standardisation and diminish varia-
tions in the acquisition, interpretation, and reporting of
WB-MRI in APC.
MET-RADS-P allows patients to be subclassified into
clinical subgroups depending on the pattern of metastatic
spread (bone, nodal, visceral, and local) for clinical trials
entry, as recommended by the Prostate Cancer Clinical
Trials Working Group (PCWG) [8]. Importantly, MET-RADS-
P promotes the collection of robust BM data informing on
clinically relevant therapy objectives, including: (1) infor-
mation on disease control with separate documentation of
progression in existing lesions and the development of new
disease, and (2) the ability to document delays in disease
progression including time to development of first metas-
tasis and time to progression for nonmetastatic castrate
resistant prostate cancer (M0-CRPC) [8]. MET-RADS-P also
allows the capture of discordant (mixed) imaging responses
and thereby provides opportunities to assess changing
tumour biology, via molecular characterisation of biopsy
tissue samples thatmay be obtained from anatomic sites on
the basis of spatial characteristics and imaging response
heterogeneity [14,15].
The specific aims of the MET-RADS-P recommendations
are to: Establish minimum acceptable technical parameters for
WB-MRI data acquisition Develop standardised data collection methods that
enables detailed descriptions of the disease phenotype
based on imaging patterns of metastatic spread (PCWG
compliance) Develop comprehensive response criteria that assess
bone, soft tissue, and local disease (PCWG compliance) Providemethods for recording the presence, location, and
extent of mixed imaging responses (to enable tumour
biopsy sampling to gain insights into mechanisms of
resistance; PCWG compliance) Summarise the likelihood of response in bone, soft
tissues, and local disease that may be used to direct
patient management Enable data collection for outcome monitoring in the
context of clinical trials (PCWG compliance) Allow the education of radiologists on WB-MRI reporting
in order to reduce variability in imaging interpretations Enhance communication with referring clinicians
 Promote quality assurance and research in APC (PCWG
compliance)
There are differences betweenMET-RADS-P proposals for
clinical trials comparedwith the recent recommendations of
PCWG (which recommends bone scan and CT assessments)
[8]. These take into account the lower spatial resolution (but
higher contrast resolution) of WB-MRI images (compared
with CT scans) and the greater complexity of evaluating and
documenting WB-MRI findings. Differences include the
minimum size of disease that is considered measureable
for response categorisations ( 1.5 cm for WB-MRI com-
pared with  1 cm for CT scanning, unless high spatial
resolution MRI methods are used), the measurement of five
non-nodal, soft tissue lesions (in total) instead of five lesions
per involved organ system, and the introduction of MRI-
based response criteria that are applicable for bone
metastases [16,17]. Detailed comparisons between MET-
RADS-P and PCWG recommendations are also highlighted in
the Supplementary data.
3. Evidence synthesis
3.1. General considerations
For the purposes of MET-RADS-P assessments, specific
imaging of the prostate or prostatectomy bed is not an
essential requirement. When there are questions regarding
persistent or recurrent local disease, a dedicated MRI can
be performed to gauge local disease extent and assess
complications.
Routine examinations of the brain are not required for
adenocarcinoma histology. The brain should be assessed in
patients with small cell/neuroendocrine tumours. There
should be a low threshold for skull base imagingwhen there
is likely to be neurological compromise.
Detailsofmachineset-up, sequence specifications, quality
assurance procedures, quality control, and radiographic
aspects are detailed in the Supplementary data and Table 2.
WB-MRI acquisitions can be tailored to the evaluation of
bones and lymph nodes (core WB-MRI protocol; Table 2,
Fig. 1) or more comprehensive assessments of the whole
body can be undertaken (Fig. 2).
The core WB-MRI protocol when used alone is designed
for bone and lymph node metastasis detection (should be
completed within 30 min of table time; Fig. 1). More
comprehensive assessments (core plus extensions) should
be used for patients with established metastatic including
visceral disease. Depending on the sequences used,
comprehensive assessments can be completed within
45–50 min of table time (Fig. 2).
The core WB-MRI protocol is adequate for the detection
of metastatic disease in the setting of biochemical recur-
rence after primary therapy, or in the setting of M0-CRPC,
Table 2 – Sequence components for whole-body magnetic resonance imaging examinations
Sequence description Core protocol Extensions for
comprehensive assessments
1 Whole spine–sagittal, T1 W, TSE, 4–5 mm slice thickness Yes –
2 Whole spine–sagittal, STIR (preferred) or fat suppressed T2W,
4–5 mm slice thickness
Yes –
3 Whole body (vertex to mid thighs)–T1 W, GRE Dixon technique. Fat
image reconstructions are mandatory
 A 3D FSE T1W sequence offering multiplanar capability may be
performed as an alternative to replace sequences 1 and 3
Axial (5 mm)a or coronal (2 mm) Axial and coronal
4 Whole body (skull base to mid-thighs)–axial, diffusion weighted,
STIR fat suppression, 5–7 mm contiguous slicing, multiple stations
 ADC calculations with mono-exponential data ﬁtting
 Coronal b800–1000 multiplanar reconstructionsb
 3D-MIP reconstructions of highest b-value imagesc
2 b-values
(b50–100 s/mm2 and b800-–1000 s/mm2)
3 b-values
(additional b500–600 s/mm2)
5 Whole body (vertex to mid thighs)–axial, T2 W, TSE without fat-
suppression, 5 mm contiguous slicing, multiple stations, preferably
matching the diffusion weighted images
Option Yes
6 Regional assessments including dedicated prostate, small ﬁeld of
view spine, brain studies, and contrast enhancement
No Yes
ADC = apparent diffusion coefﬁcient; FSE = fast spin echo; GRE = gradient echo; MIP = maximum intensity projection; STIR = short tau inversion recovery;
TSE = turbo spin echo; W = weighted; 3D = three dimensional.
a 5–7 mm, axial imaging may be chosen to match section thickness of diffusion weighted imaging to facilitate image review.
b b800–1000 images from all diffusion imaging stations are grouped and reconstructed as contiguous, two-dimensional coronal, 5-mm slices.
c Whole body three-dimensional maximum intensity projection images, displayed as rotating images, using an inverted grayscale.
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Comprehensive assessments are recommended for known
metastatic disease and for those patients in whom serial
tumour response assessments (including clinical trials) are
planned (see Supplementary data for clinical indications for
WB-MRI and respective protocol suggestions).
[(Fig._1)TD$FIG]
Fig. 1 – Typical core whole-body magnetic resonance imaging (MRI) protocol d
man previously treated with low dose rate brachytherapy for prostate cancer,
Good performance status: PS-1. Clinical question: suitability for salvage therap
scanner (30 min). Panels 1 and 2: sagittal short tau inversion recovery and T1
in the T8 vertebral body (arrow). The lower signal in the centre of the lesion o
mineralisation. No other spinal lesions are visible. Panel 3: coronal T1W gradie
a right hip replacement (asterisk). Panel 4: coronal b900 diffusion weighted im
acquired b900 images) showing multiple hyperintense foci consistent with bon
(asterisk) is larger than on the T1W-gradient-recalled echo but only obscures t
stack was reconstructed as a three-dimensional maximum intensity projection
sagittal projection MIP images show multiple bone metastases (as dark focal a
Note that the dark signal of the brain, spleen, spinal cord, and testicles is a no
axilla, and groin. Given the presence of extensive bone metastases, there is no3.2. Clinical information
The following information should be available to radiolo-
gists at the time of reporting: tumour histology (and
reclassifications of histology) and clinical indication(s) for
performing the study.epicting extensive metastatic bone disease. Clinical details: 76-yr-old
now with biochemical recurrence (prostate-specific antigen 8.9 ng/ml).
y. Typical core whole-body MRI examination undertaken using a 1.5T
weighted (W) turbo spin-echo images of the spine showing a metastasis
n the short tau inversion recovery image is consistent with
nt-recalled echo sequence shows the presence of a metal artefact from
age (multiplanar reconstruction [MPR] from a stacked series of axially
e metastases. Note that the artefact from the right hip replacement
he image locally. Panels 5 and 6: the diffusion weighted b900 image
(MIP) image and displayed using an inverted blue scale. Coronal and
reas) that are seen in the spine, pelvis, sternal bone, and left femur.
rmal finding, as are the small but prominent lymph nodes in the neck,
need for dedicated local restaging prostate MRI.
[(Fig._2)TD$FIG]
Fig. 2 – Typical comprehensive whole-body magnetic resonance imaging protocol depicting extensive metastatic bone disease. Clinical details: 73-yr-old
man with known prostate cancer recurrence, bone and nodal metastases on abiraterone treatment, and rising prostate-specific antigen (49.9 ng/ml).
Restaging examination. Typical comprehensive whole-body magnetic resonance imaging examination undertaken using a 3.0T scanner (45min).
(A) Panels 1 and 2: zoomed sagittal T1 weighted (W) turbo spin-echo and sagittal short tau inversion recovery (STIR) images of the spine showing
multiple metastases with proximal caudal equina impingement at L1. General narrowing of the lumbar spinal canal due to disc degeneration. Panel 3:
coronal T1W gradient-recalled echo (GRE) sequence shows the metastasis at L1 (horizontal arrow) but the deposits in the adjacent vertebrae are less
conspicuous. Deposits are visible in the sacrum and in both ischia (slanting arrows). Panel 4: coronal b900 diffusion weighted image (multiplanar
reconstruction [MPR]) showing multiple hyperintense foci at the bone metastatic sites (except the left ischium). Panels 5 and 6: b900 three
dimensional MIP images with coronal and sagittal projections confirm multiple bone metastases (as dark regions). Note that the dark signal of the
brain, spleen, spinal cord, and testicles is a normal finding, as are the small lymph nodes in the neck, axillae, and groin. (B) Zoomed T1W images
obtained using the Dixon technique with in-phase (IP), opposed-phase (OP), water only (WO), and fat only (FO) reconstructions at the level of the
sacrum. Multiple sacral and iliac bone metastases are seen (best depicted on the T1W-IP and FO images; arrows). (C) Zoomed T2W and b900 images in
the top row at the same level as B. Increased conspicuity of the metastases on the diffusion weighted b900 image (arrows) due to suppression of the
background fat signal. The T1W-fat% (F%) image is calculated using the T1W-wWOand T1W-FO images from B. Small amounts of F are visible with the
deposits in the iliac bones on the F% image (arrows on F% image).
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relevant clinical state of patients including whether castrate
naive or castrate resistant, symptom sites, and descriptions
of the known anatomic distribution of the disease (local,
nodal, or distant) should be indicated.
Prostate-specific antigen (PSA) levels should be known
and in the setting of M0-CRPC, the PSA-doubling time
(PSADT) should be indicated as needed, because short
PSADT is strongly associated with a higher likelihood of
metastasis development and progression.Prior and ongoing therapies received including details of
the treatment for the primary tumour, radiotherapy loca-
tions, and surgical interventions, should be known. All
current hormonal and chemotherapy medications should
also be specified (eg, radiologists may not be aware that
antiandrogens are almost never stopped when treatments
are changed, or that steroid supplementation and steroid
switching is part of abiraterone therapy, which alters bone
marrow fat composition and causes osteoporosis). Support-
ive medications including steroids, blood transfusion, and
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 8 1 – 9 286the use of bone marrow growth factors, should also be
indicated as they too affect image appearances.
3.3. Assessing WB-MRI images
Multi-sequence evaluations should be undertaken of all
diffusion weighted (DW)-MR images (low b-value, inter-
mediate [if obtained] and high b-values, and apparent
diffusion coefficient [ADC] maps) in conjunction with the
anatomical and relative F% images, using image linking and
scrolling workstation facilities and coregistration tools as
diagnostic aids (Fig. 2).
Radial maximum intensity projections of high b-value
images displayed using the inverted scale are useful for
global tumour volume assessments and for localising
regional tumour distribution. These images are able to
display disease within the soft tissues of the pelvis, lymph-
nodes, and distant bone metastases. Maximum intensity
projections images should not be used alone for disease
assessments because false positive and false negative can
occur (vide infra).
The evaluation of source b800–1000 value images of
DW-MRI sequences is based on comparing high b-value
image intensity to adjacent muscle signal intensity, but
assessments of ADCmaps is numeric (unit:  103mm2/s or
mm2/s).
The definitions for hypointense and hyperintense signal
on b800–1000 value images remains subjective but can be
gauged by using adjacent muscle as the reference back-
ground tissue [18,19].
It must be borne in mind that not all hyperintense bone
lesions on high b-value images are malignant in nature.
Causes for apparent high b-value false-positive focal bone
lesions include bone marrow oedema caused by fractures,
osteoarthritis, infection, bone infarcts, vertebral haeman-
giomas, and isolated bone marrow islands [20].
Strategies for mitigating against these false-positive
hyperintensities include direct correlationswithmorphologic
appearances including T1 weighted (W)-fast spin echo,
opposed-phase gradient-recalled echo, relative fat (F)%
images [21,22], and ADC values (ADC values of normal bone
marrow are generally below 600–700 um2/s and viable
tumour lies between 700 um2/s and 1400 um2/s; tumour
ADC values  1400 um2/s is usually observed in treated/
necrotic disease). Every suspicious lesion on high b-value
images shouldbeevaluatedusing coregistration tools (Fig. 2).
It must be noted that not all bone metastases are
hyperintense on b800–1000 value images. This may occur
because of sparse tumour cell infiltration, dense matrix
mineralisation (de-novo or related to bisphosphonate/
denosumab usage), when there is significant necrosis
(de-novo or after therapies), or whenmetastases are healed.
The potential for error in detecting metastases can be
mitigated by the evaluations of all the images obtained
including anatomic findings, intermediate b-value images
(if obtained), and relative F% images [12].
The presence of metastases can also be obscured when
background bone marrow hyperplasia occurs with the use
of bone marrow growth factors (Supplementary Fig. 2). Thedetection of skeletal metastases on WB-diffusion weighted
imaging (DWI) may also be impaired in areas of body
movement such as the ribs and occasionally in the sternum.
Skull vault metastasis evaluations are best undertaken by
evaluating the axial source high b-value images. The
visibility of skull base disease is additionally impaired
because of susceptibility effects.
3.3.1. Obtaining ADC values
ADC measurements should only be obtained from metasta-
ses when water is detectable on DWI (all b-value images
should be examined); otherwise the ADC values will be
erroneous, reflecting only the noise in the images. Thus,
dense sclerotic metastases without signal intensities detect-
able on DWI should not have their ADC measured.
The absence of tissue signal intensity on very high
(b800–1000) b-value images does not invalidate a tissue
from ADC measurements, provided that signal intensity
is detectable on low and intermediate b-value images
(see Supplementary Fig. 3 for the importance of such
measurements).
The authors recognise that there are limitations of the
ADC cut-off values referred to above, which are partly
related to the fact that ADC values depend on the choice of
b-values of DWI used for calculations (hence the constraints
on the b-values choices recommended). The authors also
recognise that ADC values may also depend on the diffusion
time achievable on diffusion sequences (which is highly
dependent on sequence waveforms and scanner specifica-
tions), on the method of fat suppression, and on a variety of
other technical factors.
When there are deviations from the recommended
b-values and fat suppression methods used due to
machine/software or technical factors, then institutions
can determine their own muscle normalised high b-value
signal intensity and ADC cut-off values of normal marrow
and for untreated bone marrow metastases [18].
3.4. Structured reporting
Relevant prior/concurrent imaging studies should be
available at the time of image assessments including bone
scans, CT studies, and PET/CT examinations. Prior WB-MRI
examinations and their reports should also be available.
Radiologists should be familiar with the normal range of
appearances on their equipment as these can vary slightly
between MRI scanners. They should also be aware of the
range of imaging artefacts that may be encountered.
It should be understood that exclusion of metastasis can
never be absolute; it is important that all those involved in
patient management recognise the limitations of WB-MRI
investigations. Radiologists working in multidisciplinary
teams are best placed to educate other caregivers on the
potential advantages and limitations for specific patient
indications.
Structured clinical and tabulated template reporting
should be undertaken for each examination. The structured,
textural WB-MRI report should comprise the following
components:
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A statement regarding the patient’s clinical state, prior
treatments including local and pelvic disease, current
pathological status, PSA/PSADT and the specific clinical
question being posed.
3.4.2. Technique
Details of the technique (core or comprehensive protocol),
including contrast medium administration, and whether or
not dedicated regional images were obtained.
Important deviations in techniques and artefacts should
be noted with their causes (eg, metal implant artefacts,
patient movement from pain, reception coil nonusage or
failure etc.), and their likely effect on imaging interpretation
should be specifically stated. If patient specific solutions for
improving image quality have already been noted, then
these should additionally be documented, so the same
image adjustments are performed at follow-up.
When comparisons are made with previous examina-
tions, the dates and regions scanned of prior studies should
be indicated.
3.4.3. Findings
WB-MRI reports are usually structured to initial evaluations
of the spine (and pelvic bones) and then head to thighs in
descending order. As a viable alternative, structuring of
reports under headings of primary site, lymph nodes
(regional and nonregional), bone, and visceral metastases
following the TNM format can also be undertaken [23].
Imaging findings should include free text but should also
include measurements of lesions. Unusual sites of sus-
pected disease should be mentioned. Clear identification of
marker lesions by anatomic location, size measurement,
and by sequence/slice number(s) as necessary (tabulated as
outlined in the Supplementary data).
Reportable elements are dependent on the protocol
employed for the WB-MRI examination. Bone, nodal
disease, visceral, and soft tissue assessments maybe
undertakenwith the appropriate caveats; inability to depict
microscopic metastases in normal sized nodes, inability to
consistently visualise lung metastases <1 cm in size,
inability to definitively exclude brain metastases in the
absence of contrast medium administration, etc.
Other pertinent, including negative, findings can be
included. The presence of complications such as renal
obstruction and likelihood of bone compromise that could
lead to a significant skeletal event should be stated.
Follow-up studies should mirror baseline assessments.
Changes in the measurements of marker lesions are an
essential part of the objective assessments of response, often
determining clinical decisions regarding therapy continua-
tion. This places extra responsibility on radiologists to
provide accurate and objective reports that enable oncologic
clinicians to use the scan information appropriately.
3.4.4. Impression or conclusion
Whenever possible, a clear, brief summary statement of the
overall assessment of the disease status indicating any
changes over time should be presented. Recommendedterms for overall patient response should encompass the
range of potential observations that incorporate on a scale,
the likely disease status (highly likely to be responding,
likely to be responding, stable, likely to be progressing,
highly likely to be progressing, and discordant).
The summary should specifically mention assessments
of the primary tumour, nodal disease (local and distant),
and visceral sites of metastatic disease. Comments on the
general trend of change, intermediate lesions, uncertainties,
and differential responses should be specifically noted.
When progression is observed, distinguish between the
emergence of new disease and growth of previously noted
disease.
The presence of complications such as renal obstruction
and likelihood of bone compromise that could lead to a
significant skeletal event should be highlighted.
Recommendations regarding follow-up duration, biopsy,
and alternative radiological studies to clarify the nature of
equivocal findings should also be made, as required.
3.5. Baseline lesion identification, mapping and measurements
At baseline, all unequivocal cancer lesions should be
assigned to their regional location using the baseline
reporting template form (Supplementary data). Fourteen
regions have been selected for assessment at baseline and
on follow-up studies: primary disease, seven skeletal
regions, five nodal and visceral, and other sites. Detailed
instruction can be found in baseline assessments methods
(Supplementary data).
Measurements of bone lesions should be undertaken on
high quality T1 W images. Lymph nodes and soft tissue
assessment should also be undertaken using the measure-
ment template form (Supplementary data). Up to five
discrete bone lesions ( 1.5 cm longest diameter) should be
chosen with at least one lesion in the appendicular skeleton
( 1.5 cm) if present. Up to five discrete lymph nodes
( 1.5 cm short axis) and up to five soft tissue lesions
( 1.5 cm; long axis) measurements can be obtained
(15 lesions maximum). Thus, the 1.5-cm threshold applies
to all measured lesions.
The 1.5-cm size threshold has been deliberately set to
account for the poorer spatial resolution of WB-MRI images
compared with whole body CT scans. Pixel sizes using
a 256  256 mm matrix at a whole body field of view of
400–440 mm, can be 1.5–2 mm for T1W and T2 W
sequences. For DWI pixel sizes are in the order of
3–4 mm. The 5–7-mm thick slice of images further
compounds partial volume averaging effects. This resolu-
tion is much less than what is achievable by routine CT
scans (0.8–1 mm), meaning that lesion size measurement
accuracy is lower forMRI. However, when spatial resolution
allows (three dimensional, fast spin echo sequences), the
1.5-cm threshold can be relaxed to 1.0 cm. Active medical
physics engagement may be necessary to clarify what can
reasonably be achieved locally.
Potential target lesion(s) should be chosen for measure-
ment recording. Nontarget lesions should be recorded but
not measured. The presence of nonmeasurable disease
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Tumours [RECIST] v1.1 guidance) [24]. Thus, lymph nodes
that are 1.0 cm but less than 1.5 cm in short axis are
considered pathologic but nonmeasureable (note that
nonmeasurable in this context refers to a specific RECIST
defined term). Visceral disease 1.5 cm in long axis is
considered as measurable but when unequivocally malig-
nant but less than <1.5 cm they are considered pathologic
but nonmeasurable. Further detailed instructions can be
found in baseline assessments methods (Supplementary
data).
In rare instances, when there are unequivocal malignant
lesions <1.5 cm and clinical trial entry mandates the
presence of measurable disease, a relaxation of the
1.5-cm threshold may be applied (minimum > 1 cm,
 1.5 cm preferred) in the knowledge of the caveats on
image resolution discussed above.
3.6. Follow-up and response assessments
3.6.1. Frequency of follow-up
In clinical trials, we suggest that WB-MRI be performed at
fixed-time intervals to better understand when and for how
long antitumour effects occur. To minimise patient expo-
sure to ineffective treatments, particularly for treatments
for which the optimal timing is unknown, periodic
assessments every 8–9 wk should be employed in clinical
trials for 6 mo, and every 12 wk thereafter (PGWG
compliant) [8].
For patients receiving clinically approved treatments,
routine 12 weekly assessments will suffice, unless there are
clinical indications for earlier re-evaluations. This recom-
mendation is consistent with recent European and Interna-
tional consensus guidelines for monitoring the progress of
APC [4,5].
For patients with M0-CRPC who are undergoing surveil-
lance to detect the emergence of metastatic disease, 16-wk
interval scanning can be undertaken (PCWG compliant) [8].
3.6.2. Response categories
Response assessments are undertaken by noting measure-
ments and observation changes at a regional level, and on a
whole patient basis, at each follow-up examination.
At each follow-up study, measurements should be
repeated, following the lesions identified on baseline
measurements (Supplementary data).
At each follow-up study, changes in the metastatic
patterns should be assessed and recorded at a regional level
using regional response assessment template forms in the
Supplementary data.
Regional level response assessments use a scale of 1–5
indicating the likely response category: (1) highly likely to
be responding, (2) likely to be responding, (3) stable,
(4) likely to be progressing, and (5) highly likely to be
progressing, using the criteria defined in Table 3.
These response assessment categories (RAC) have been
designed to capture regional responses for both bone and
soft tissue assessments; further details on use of RAC
categories are found in the Supplementary data.3.6.3. Discordant response assessments
MET-RADS-P incorporates a scoring system that enables
documentation of heterogeneity of responses (mixed/
discordant responses) at the regional level using RACs.
A three pattern scoring system that records responses
should be used (primary [dominant]/secondary/tertiary).
The primary/dominant pattern is the response (on the RAC
1–5 scale) seen in themajority of lesionswithin regions. The
secondary pattern records the second most frequent RAC
pattern of response within the region (Supplementary
Table 2).
When there are three patterns in a region, and the
tertiary is RAC 1–3, this tertiary pattern can/should be
ignored as a minor response/stable disease is unlikely to
be prognostically important. Thus, the tertiary pattern
should only be used to document progressing/progressive
disease (RAC patterns 4 and 5) occurring in a minority of
lesions in a region (when not already recorded on the
primary or secondary assessments).
3.7. Final response assessment
The status of the primary disease, nodes, viscera, and bone
disease should be recorded separately using the overall
response assessment template form (Supplementary data).
Note that there is no separate recording of overall patient
response on the form, which should be indicated in the text
report (see section 3.4 above) taking into account the
overall imaging impressions.
3.7.1. Soft tissue disease
Unlike regional response assessments, overall response for
the primary tumour, nodal, and visceral disease should be
categorical, thus following established guidelines (PCWG
modifications of RECIST v1.1) [8]. The following categories
should be assigned: complete response, partial response,
stable disease, progressive disease, and discordant.
Any progression assignment in soft tissues based on
measurements should be from baseline or treatment
induced nadir whichever is lower. Overall progression
based on measurements is the only time when treatment
induced nadir is used. Other progression assignments are as
per RECIST v1.1 (including new disease).
3.7.2. Bone disease
Unlike soft tissue assessments, the overall response of bone
disease should be on a scale of 1–5 indicating the likely
overall response category: (1) highly likely to be respond-
ing, (2) likely to be responding, (3) stable, (4) likely to be
progressing, (5) highly likely to be progressing, and
(6) discordant. This overall bone assessment should be
based on the regional assessments using the criteria in
Table 3.
3.7.3. Discordant response
Discordance indicates the presence of progressing bone/soft
tissue disease, not meeting definitive progression criteria in
the primary category, that is, when themajority of disease is
stable or responding.
Table 3 – METastasis Reporting and Data System for Prostate Cancer regional response assessment categories
RAC Classiﬁcation Region Descriptionsa
1 Highly likely to be responding Local, nodal,
and visceral
 Consistent with RECIST v1.1/PCWG criteria for unequivocal response (partial/complete; see
below)
Bone Return of normal marrow in areas previously inﬁltrated by focal/diffuse metastatic inﬁltration
 Decrease in number/size of focal lesions sufﬁcient to indicate high likelihood response
 Evolution of diffuse neoplastic pattern to focal lesions
Decreasing soft tissue associated with bone disease
 Dense lesion sclerosis (edge to edge), sharply deﬁned, very thin/disappearance of hyperintense
rim on T2W-FS images
 The emergence of intra/peritumoural fat within/around lesions (fat dot/halo signs)
 Previously evident lesion shows increase in ADC from 1400 mm2/s to >1400 mm2/sb
 40% increase in ADC from baseline with corresponding decrease in high b-value SI; and
morphological ﬁndings consistent with stable or responding diseasec
2 Likely to be responding Local, nodal,
and visceral
 Changes depicting tumour response that do not meet RECIST v1.1/PCWG criteria for partial or
complete response (see below)
Bone Evidence of improvement, but not enough to fulﬁl criteria for RAC 1. For example:
 Previously evident lesions showing increases in ADC from 1000 mm2/s to <1400 mm2/sb
 >25% but <40% increase in ADC from baseline with corresponding decrease in high b-value SI;
and morphological ﬁndings consistent with stable or responding diseasec
3 No change All  No observable change
4 Likely to be progressing Local, nodal,
and visceral
 Changes depicting tumour progression that do not meet RECIST v1.1/PCWG criteria for
progression (see below)
Bone  Evidence of worsening disease, but not enough to fulﬁl criteria for RAC 5
 Equivocal appearance of new lesion(s)
 No change in size but increasing SI on high b-value images (with ADC values < 1400 mm2/s)
consistent with possible disease progressionb
 Relapse disease: re-emergence of lesion(s) that previously disappeared or enlargement of
lesion(s) lesions that had partially regressed/stabilized with prior treatments
Imaging depicted bone lesions that might be clinically signiﬁcant (therefore excludes
asymptomatic fractures in noncritical bones)
 Soft tissue in spinal canal causing narrowing not associated with neurological ﬁndings and not
requiring radiotherapy
5 Highly likely to be progressing Local, nodal,
and visceral
 Changes depicting tumour progression that meet RECIST v1.1/PCWG criteria for unequivocal
progression (see below)
Bone  New critical fracture(s)/cord compression requiring radiotherapy/surgical intervention! only if
conﬁrmed as malignant by MRI signal characteristics
 Unequivocal new focal/diffuse area(s) of metastatic inﬁltration in regions of prior normal marrow
 Unequivocal increase in number/size of focal lesions
Evolution of focal lesions to diffuse neoplastic pattern
 Appearance/increasing soft tissue associated with bone disease
 New lesions/regions of high signal intensity on high b-value images with ADC value between
600 mm2/s and 1000 mm2/s
RECIST v1.1 categories [24]
 Complete response: disappearance of all target lesions
 Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD
 Stable disease: neither sufﬁcient shrinkage to qualify for partial response nor sufﬁcient increase to qualify for progressive disease, taking as reference the
smallest sum LD since the treatment started
 Progressive disease: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment
started or the appearance of one or more new lesions
Progression of local prostate disease
 Use RECIST v1.1 for progression criteria above applied to local disease
Progression of nodes
 <1.0 cm nodes have to have grown by at least 5 mm in short axis from baseline or treatment nadir and be 1 cm to be considered to have progressed
 For nodes that are 1.0–1.5 cm that have grown by at least 5 mm in short axis from baseline or treatment nadir and are 1.5 cm in short axis can be
considered to have progressed
 For nodes 1.5 cm short axis use RECIST v1.1 progression criteria
Progression of visceral disease
 Use RECIST v1.1 progression criteria above applied to visceral disease
ADC = apparent diffusion coefﬁcient; FS = fast spin; MRI = magnetic resonance imaging; PCWG = Prostate Cancer Clinical Trials Working Group; RAC = response
assessment category; RECIST = Response Evaluation Criteria in Solid tumours; SI = signal intensity; W = weighted.
a Multiple criteria need to be met to category response.
b Apparent diffusion coefﬁcient cut-off values determined by measurements of untreated lesions [18,41,42].
c Based on the reproducibility of apparent diffusion coefﬁcient values of <20% [43,44].
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only be applied for stable and partial response categories to
reflect its prognostic importance. Similarly, for bone
disease, the discordant category should only be applied
for stable and responding categories.Discordance should be separately reported for primary,
nodal, viscera, and bone; evaluations of regional discordant
responses on forms in the Supplementary data will enable
the specific identification of the anatomic sites of mixed
responses.
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a secondary (ie, major discordance) or tertiary (ie, minor
discordance) assessment (Supplementary Table 2).
4. Conclusions
The MET-RADS-P system provides comprehensive char-
acterisation of APC state, not only at the start of
treatments, but also over time as the disease evolves.
MET-RADS-P is suitable for guiding patient care (using
the regional and overall assessment criteria), but can also
be incorporated into clinical trials when lesion measure-
ments become more important. MET-RADS-P allows the
categorisation of patients with specific patterns of disease
for clinical trials stratification. MET-RADS-P enables the
evaluation of the benefits of continuing therapy, when
there are signs that the disease is progressing (discordant
responses).
MET-RAD-P requires validation within clinical trials.
We suggest that MET-RADS-P be evaluated in studies that
assess the effects of treatments known to kill tumour cells
such as those targeting the androgen axis and cytotoxic
chemotherapy. In these studies, MET-RADS-P should be
compared with other response BMs, and correlated to
quality of life measures, rates of skeletal events, and
progression free survival. The latter are prerequisites for
the introduction of WB-MRI into longer term follow-up
studies that prospectively collect appropriate meta-data,
which would allow objective assessments of whether
WB-MRI is effective in supporting drug development.
Clearly, MET-RADS-P is not at the point where it can
support regulatory approvals of new therapeutic
approaches. It is anticipated that, as evidence accrues
from clinical trials, more specific recommendations and/
or algorithms incorporating MET-RADS-P will emerge.
Thus, we recommend that MET-RADS-P is now evaluated
in clinical trials, to assess its impact on the clinical
practice of APC.
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